Performance of highly sensitive cardiac troponin T assay to detect ischaemia at PET-CT in low-risk patients with acute coronary syndrome: a prospective observational study. by Morawiec, B. et al.
 1Morawiec B, et al. BMJ Open 2017;7:e014655. doi:10.1136/bmjopen-2016-014655
Open Access 
AbstrAct
Background Highly sensitive troponin T (hs-TnT) 
assay has improved clinical decision-making for 
patients admitted with chest pain. However, this assay’s 
performance in detecting myocardial ischaemia in a 
lowrisk population has been poorly documented.
Purpose To assess hs-TnT assay’s performance to 
detect myocardial ischaemia at positron emission 
tomography/CT (PET-CT) in low-risk patients admitted 
with chest pain.
Methods Patients admitted for chest pain with a 
nonconclusive ECG and negative standard cardiac 
troponin T results at admission and after 6 hours 
were prospectively enrolled. Their hs-TnT samples 
were at T0, T2 and T6. Physicians were blinded to 
hs-TnT results. All patients underwent a PET-CT at 
rest and during adenosine-induced stress. All patients 
with a positive PET-CT result underwent a coronary 
angiography.
Results Forty-eight patients were included. Six had 
ischaemia at PET-CT. All of them had ≥1 significant 
stenosis at coronary angiography. Areas under the 
curve (95% CI) for predicting significant ischaemia 
at PET-CT using hs-TnT were 0.764 (0.515 to 
1.000) at T0, 0.812(0.616 to 1.000) at T2 and 
0.813(0.638 to 0.989) at T6. The receiver operating 
characteristicbased optimal cut-off value for hs-
TnT at T0, T2 and T6 needed to exclude significant 
ischaemia at PET-CT was <4 ng/L. Using this value, 
sensitivity, specificity, positive and negative predictive 
values of hs-TnT to predict significant ischaemia were 
83%/38%/16%/94% at T0, 100%/40%/19%/100% at T2 
and 100%/43%/20%/100% at T6, respectively.
Conclusions Our findings suggest that in low-risk 
patients, using the hs-TnT assay with a cut-off value of 
4 ng/L demonstrates excellent negative predictive value 
to exclude myocardial ischaemia detection at PET-CT, at 
the expense of weak specificity and positive predictive 
value.
Trial registration number  ClinicalTrials. gov Identifier: 
NCT01374607.
IntroductIon
Patients presenting with symptoms suggestive 
of acute coronary syndrome (ACS) repre-
sent a large population of those admitted to 
emergency departments.1 Recent available 
high-sensitive troponin T (hs-TnT) assay 
has improved the detection of patients with 
acute myocardial infarction (AMI) in terms 
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Strengths and limitations of this study
 ► In this study, we showed an additive diagnostic 
value of high-sensitive troponin T over standard 
troponin in detection of myocardial ischaemia as 
assessed by the gold standard imaging modality—
positron emission tomography/CT (PET-CT) in a 
clinically difficult population of patients with chest 
pain, non-conclusive ECG and negative standard 
cardiac troponin and low risk of an acute coronary 
syndrome (ACS).
 ► Even within a normal range of high-sensitive 
troponin T concentration, a cut-off level may be 
identified to further improve diagnostic accuracy 
and reduce false-negative and false-positive results 
indicative for myocardial ischaemia as assessed by 
PET-CT.
 ► We provide data, supported by the PET-CT study, on 
non-inferiority of the shortening of troponin protocols 
for ruling out an ACS in the emergency department 
from 6 to 2 hours interval.
 ► The study sample and single-centre character of the 
study warrants careful interpretation of outcomes 
and further research on larger population, preferably 
multicentric.
 ► Time intervals of blood sampling were adopted 
from European guidelines so the implementation of 
outcomes is limited in respect to ongoing research 
on different strategies maximally shortening 
diagnostic protocols.
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of its speed and sensitivity over standard cardiac troponin 
(cTn) assays.2 The hs-TnT assay was recently incorporated 
into the clinical decision algorithm of the latest Euro-
pean Society of Cardiology (ESC) guidelines.3 However, 
despite its better sensitivity, the hs-TnT assay has a lower 
specificity because positive values are driven by several 
non-coronary cardiac and non-cardiac clinical condi-
tions. The introduction of the hs-TnT assay has therefore 
led to more false-positive results and subsequent unnec-
essary hospitalisations. When cardiac troponin levels are 
negative at different time points, current recommen-
dations propose using a stress imaging test to identify 
patients at risk of cardiac events. The added value of the 
hs-TnT assay over the standard cTn assay in this popula-
tion of patients is poorly documented, however. The aim 
of this study was therefore to assess the performance of 
the hs-TnT assay to detect myocardial ischaemia at posi-
tron emission tomography/CT (PET-CT) in a population 
of patients admitted for chest pain with negative standard 
cTn.
MaterIals and Methods
trial oversight
The study was conducted after regulatory and ethical 
approval was obtained from the local ethical commission 
(protocol 18/11) and it was duly registered on  clinical-
trial. gov ( ClinicalTrials. gov Identifier: NCT01374607).
sample population
Patients admitted to the emergency department for chest 
pain were prospectively enrolled in the study. Inclusion 
criteria were: acute chest pain lasting ≥5 min within the 
last 24 hours and negative standard cTn results at admis-
sion (T0) and after 6 hours (T6). Exclusion criteria 
were: ST-segment elevation myocardial infarction; major 
organ dysfunction, infection or major medical conditions 
(uncontrolled asthma, severe chronic obstructive pulmo-
nary disease, AV-block of the II or III degree without a 
pacemaker) that would compromise the patient's ability 
to undergo a hyperemic, adenosine-induced stress test; 
cancer with expected survival <6 months; pregnancy or 
age <18 years. At admission, a clinical examination was 
performed and an ECG was used to screen for acute 
myocardial ischaemia according to international stan-
dards.4 Information on cardiovascular risk factors, any 
past medical history of cardiovascular diseases and current 
medical treatment were collected. All patients were 
stratified according to their thrombolysis in myocardial 
infarction (TIMI) risk score and the score of 0 or 1 was 
indicative for low risk of cardiovascular adverse events.5
troponin measurements
The standard cTn assay, routinely used in the institu-
tion throughout the enrolment process, was cardiac 
troponin I measured with AccuTnI assay (Beckman 
Coulter, Fullerton, California, USA), with a 99th percen-
tile level of 0.04 µg/L and a 20% coefficient of variation 
at 0.03 µg/L and considered as positive if above the 99th 
percentile. The hs-TnT value was measured in parallel to 
the standard cTnI assay, using the same plasma samples 
at T0, T2 and T6. Concentrations of hs-TnT in plasma 
were measured using a Cobas e602 immunoanalyzer 
(Roche, Basel, Switzerland) based on electrochemilumi-
nescence technology (detection range of 3–10 000 ng/L, 
with a 99th percentile level in a normal population 
of 14 ng/L and a 10% coefficient of variation level of 
13 ng/L). The 2-hour diagnostic protocol using cTn has 
been described previously to carry a good diagnostic 
accuracy.6
Pet-ct and coronary angiography
All patients underwent a rubidium-82 (Rb-82) rest–
stress cardiac PET-CT acquisition (Discovery 690, GE 
Healthcare, Milwaukee, Wisconsin, USA) according to a 
previously described method.7 Patients were instructed to 
fast for 6 hours and the absence of any caffeine intake in 
the previous 24 hours was checked. Dynamic rest acquisi-
tion started after the beginning of an intravenous infusion 
of 10 MBq/kg of Rb-82 (Jubilant Draximage, Kirkland, 
Canada).8 Ten minutes later, a hyperaemic stress test was 
performed using a slow intravenous infusion of adenosine 
(140 µg/kg/min) over 6 min. A second PET-CT acquisi-
tion was started 2 min after the beginning of adenosine 
infusion. PET-CT images were analysed semi-quantitatively 
by two independent nuclear medicine specialists using 
the 17-segment AHA polar map9 to reveal the extent and 
severity of perfusion defects at rest (summed rest score 
(SRS)) and during stress (summed stress score (SSS)), 
as well as inducible ischaemia as defined by the summed 
difference score (SDS=SSS-SRS). Absolute quantitation 
of myocardial blood flow (MBF) at rest and during stress, 
as well as the myocardial flow reserve (MFR=stress MBF/
rest MBF), were computed using FlowQuant (Ottawa 
Heart Institute, Ottawa, Canada). Both, SDS and MFR 
have been documented as having a prognostic value in 
patients investigated for ischaemia.7 10 A PET-CT is likely 
to be positive for myocardial ischaemia when SDS is >2 or 
MFR is <1.8. These two thresholds have been shown to 
be strong predictors of major cardiovascular events.7 11 
Patients in the present study who were positive for myocar-
dial ischaemia on PET-CT images were scheduled for a 
coronary angiography.
The results of coronary angiography were assessed visu-
ally by two independent investigators, with an assessment 
by a third interventional cardiologist in cases of border-
line stenosis. Stenosis of an epicardial coronary artery 
was defined as significant if the diameter of the stenosis 
was >50% of the lumen diameter in an artery with a diam-
eter >2 mm.
Major adverse cardiac events
Patients were followed-up with phone calls 30 days after 
discharge and evaluated for any major adverse cardio-
vascular event (MACE), defined as rehospitalisation 
for a cardiovascular reason, repeated revascularisation, 
non-fatal AMI or death of a cardiovascular origin.
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Table 1 Patients’ clinical characteristics
Characteristic Total population (n=48) Without ischaemia (n=42) With ischaemia (n=6)
Past medical history
  Myocardial infarction 3 (6%) 1 (2%) 2 (33%)
  Percutaneous coronary intervention 15 (31%) 12 (29%) 3 (50%)
  Coronary artery bypass grafting 1 (2%) 1 (2%) 0 (0%)
  Peripheral artery disease 1 (2%) 0 (0%) 1 (17%)
  Stroke 2 (4%) 1 (2%) 1 (17%)
  Renal insufficiency 1 (2%) 1 (2%) 0 (0%)
Cardiovascular risk factors
  Arterial hypertension 28 (58%) 22 (52%) 6 (100%)
  Dyslipidemia 26 (54%) 20 (48%) 6 (100%)
  Diabetes 7 (15%) 6 (14%) 1 (17%)
  Familial history 15 (31%) 14 (33%) 1 (17%)
  Current/former smoking 20 (42%) 18 (43%) 2 (33%)
  TIMI risk score 1 (0 to 2) 0 (0 to 0) 2 (2 to 3)
  Clinical presentation
  Systolic blood pressure 135 (119 to 155) 135 (122 to 152) 142 (129 to  154)
  Diastolic blood pressure 75 (66 to 82) 75 (69 to 82) 64 (62 to 78)
  Heart rate 72 (60 to 88) 73 (62 to 88) 65 (53 to 75)
  Body mass index 27.8 (25.3 to 30.4) 27.3 (25.3 to 29.8) 28.8 (26.5 to 30.7)
Data are presented as n (%) or median (25th; 75th percentile).
TIMI, thrombolysis in myocardial infarction.
statistics
Statistical analysis was performed using SPSS software 
(V.19, SPSS, Chicago, Illinois, USA) and GraphPad Prism 
V.6.0 (GraphPad Software, La Jolla, California, USA). 
Variables are presented as a mean±SD or as a median and 
its IQR. Comparisons between groups were performed 
using the Mann-Whitney U test for continuous variables. 
Comparisons of categorical data were performed using 
the Fischer's exact test or the χ2 test, as appropriate. A 
bilateral p value <0.05 was considered to be statistically 
significant. Receiver operating characteristic (ROC) 
curves were constructed by plotting each patient’s values 
of hs-TNT at T0, T2 and T6 against the presence of isch-
aemia at PET-CT. Best cut-offs were calculated using 
Youden’s index.
results
clinical characteristics of the sample population
Of 50 eligible patients, 2 were excluded due to technical 
problems during the PET-CT quantitation of flow reserve. 
The remaining 48 patients participating in the study had 
a median (P25; P75) duration of chest pain of 2 hours (1; 
4); mean age was 58±13 years; 33 (68%) were males; 7 
(15%) had diabetes; 3 (6%) had a history of myocardial 
infarction; 15 (31%) had prior percutaneous coronary 
intervention and 1 (2%) had prior coronary artery bypass 
graft. The median TIMI risk score was 1 (0; 2) (table 1).
levels of hs-tnt in the sample population
As per the study design, standard cTn levels were <99th 
percentile (<0.03 mg/L) in all patients at T0 and T6. 
First blood sample for hs-TnT measurement was taken 
after a median of 4 hours 8 min after first chest pain and 
after a median of 1 hour 28 min after the last episode. 
Median hs-TnT levels for the sample population were 
6.0 (3.0 to 9.0) ng/L at T0; 5.5 (3.0 to 9.0) ng/L at T2, 
and 5.0 (3.0 to 9.0) ng/L at T6. These hs-TnT values 
remained stable over time, with a mean absolute change 
of 0.29 ng/L within the first 2 hours after admission, and 
of 0.021 ng/L in the following 4 hours (Figure 1).
Identification of inducible ischaemia with Pet-ct
A PET-CT was performed with a median delay of 32 hours 
(17 to 65) from symptom onset. Among the 48 patients, 6 
(12.5%) had a positive PET-CT for myocardial ischaemia 
(Figure 2). In all patients diagnosed positive for myocar-
dial ischaemia, a coronary angiography confirmed at least 
one significant epicardial coronary artery stenosis.
roc curves
Areas under the ROC curves were calculated for hs-TnT 
at T0, T2 and T6, both with and without absolute delta 
changes. The areas under the curves (95% CI) obtained 
were: 0.764 (0.515 to 1.000) (T0); 0.812 (0.616 to 1.000) 
(T2); 0.806 (0.601 to 1.000) (T0, T2 and delta change); 
0.813 (0.638 to 0.989) (T6) and 0.829 (0.634 to 1.000) 
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Figure 1 Plot of highly sensitive troponin T concentrations 
at admission (T0) and at 2 hours (T2) and 6 hours (T6) 
afterwards. PET-CT, positron emission tomography/CT.
Figure 2 Study chart. PET-CT, positron emission 
tomography/CT.
Figure 3 Receiver operating characteristic curves for the 
detection of myocardial ischaemia. AUC, area under the 
curve; hs-TnT, highly sensitive troponin T.
(T0, T2, T6 and delta changes) (Figure 3). Additional 
analyses with different absolute values for hs-TnT and 
incorporation of the absolute delta changes improved 
the area under the curves, but these differences were not 
statistically significant.
sensitivity, specificity, positive predictive value, negative 
predictive value and diagnostic accuracy
The ROC-based, optimal cut-off value for hs-TnT value 
at T0, T2 and T6 necessary to exclude a diagnosis of 
significant ischaemia at a PET-CT was <4 ng/L. Such 
concentration was met by 17 (35%) patients at T0 and 
T2 and 18 (38%) patients at T6. Using this value, the 
sensitivity, specificity and positive and negative predic-
tive values of the hs-TnT assay to predict significant 
ischaemia at PET-CT were 83 (36% to 99%), 38 (24% 
to 54%), 16 (6% to 34%), 94 (69% to 100%) at T0, 100 
(52% to 100%), 40 (26% to 57%), 19 (8% to 38%), 
100 (77% to 100%) at T2 and 100 (52% to 100%), 43 
(28% to 59%), 20 (8% to 39%), 100 (78% to 100%) at 
T6 (table 2). Using the recommended cut-off value of 
the 99th percentile at 14 ng/L, the sensitivity, specificity, 
positive and negative predictive values of the hs-TnT 
assay were 50 (14% to 86%), 93 (79% to 98%), 50 (14% 
to 86%), 93 (79% to 98%) at T0, 50 (14% to 86%), 95 
(83% to 99%), 60 (17% to 93%), 93 (79% to 98%) at 
T2 and 50 (14% to 86%), 93 (79% to 98%), 50 (14% to 
86%), 93 (79% to ;98%) at T6.
The performance accuracy of different hs-TnT 
cut-off values was assessed at T0, T2 and T6 (Figure 4). 
The highest prediction values at T0, T2 and T6 were 
observed with cut-off values of 19, 18 and 21 ng/L, 
respectively, with a performance accuracy of 91.6% for 
each time point.
Follow-up
During the 30-day follow-up period, no adverse cardiovas-
cular events were reported in any of the 48 patients.
dIscussIon
The recently introduced hs-TnT assays are the most 
sensitive markers of myocardial necrosis. Their recom-
mendation in European guidelines for ACS management3 
has been validated by several clinical trials that showed 
the assay’s high diagnostic accuracy2 12 and greater prog-
nostic accuracy than standard cTn assay.3 However, the 
hs-TnT assay’s diagnostic performance for the detection 
of myocardial ischaemia in a low-risk profile population 
had been poorly documented. We chose myocardial blood 
flow quantitation, using a Rb-82 PET-CT, as a non-invasive 
stress test to detect myocardial ischaemia.
The present study showed that hs-TnT assay measure-
ments in a population of low-risk ACS profile patients at T0, 
T2 and T6 provided low specificity and low positive predic-
tive values but an excellent sensitivity and negative predictive 
values (94%, 100% and 100%, respectively) for predicting 
the detection of ischaemia as assessed using a PET-CT at a 
cut-off of 4 ng/L. Moreover, measurements at T2 provided 
higher negative predictive values than at T0 and equal to 
values at T6. In other words, T2 might be considered as 
potentially valuable time point at which to exclude isch-
aemia in this specific population but this finding warrants 
further studies on larger cohorts.
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Table 2 The hs-TnT assay’s performance in predicting the detection of ischaemia at PET-CT
hs-TnT ≥4 ng/L at: T0 T2 T6
Sensitivity 83.33% (36.48 to 99.12) 100% (51.68 to 100.00) 100% (51.68 to 100.00)
Specificity 38.10% (23.99 to 54.35) 40.48% (26.02 to 56.65) 42.85% (28.08 to 58.93)
Positive predictive value 16.13% (6.09 to 34.47) 19.35% (8.12 to 38.06) 20% (8.40 to 39.13)
Negative predictive value 94.12% (69.24 to 99.69) 100% (77.08 to 100.00 to) 100% (78.12 to 100.0 to)
Area under the curve 0.76 (0.52 to 1.00) 0.81 (0.62 to 1.00) 0.81 (0.64 to 0.99)
hs-TnT, highly sensitive troponin T; PET-CT, positron emission tomography/CT.
Figure 4 Diagnostic accuracy. hs-TnT, highly sensitive 
troponin T.
Current European guidelines on the management of 
ACS in patients presenting without persistent ST-seg-
ment elevation have introduced algorithms for ruling-in 
and ruling-out acute myocardial infarction. In patients 
with hs-TnT levels below the 99th percentile, without 
ischaemic changes on ECGs and free of chest pain for 
several hours, these guidelines propose a stress imaging 
test at the time of admission or shortly after discharge. 
Nevertheless, the exact timing of these investigations 
remains unclear and the treatment regimen during a 
potential discharge remains a typical daily dilemma for 
clinicians. Indeed, a recent prospective study based on 
data from 1400 patients with unstable angina suggested 
that adherence to the ESC guidelines was inadequate in 
nearly two-thirds of patients in terms of overtreatment 
or undertreatment.13 In a retrospective study based 
on 344 patients with chest pain, negative serial ECG 
and negative cardiac enzyme discharged before stress 
testing, 2 patients had a fatal out-of-hospital cardiac 
event and 24 were readmitted to the emergency depart-
ment prior to carrying out stress testing.14 In addition, 
data based on 966 patients with unstable angina who 
were mistakenly discharged were analysed as part of a 
multicentre trial. Their risk-adjusted mortality ratio 
was 1.7 times higher than those who were hospitalised 
(95% CI 0.2 to 17.0).15 Different studies evaluating the 
safety of discharge before stress testing based solely on 
negative hs-TnT values have been recently published. In 
a general population of patients suspected for ACS, it 
was documented that single normal troponin measure-
ment at admission (below the 99th percentile) was not 
a reliable method to safely rule-out patients suspected 
for ACS.16 The safety of ruling-out an ACS was also 
examined in regard to undetectable levels of hs-Tn at 
admission, showing high negative predictive value for 
this strategy.17 18 The present study identified a cut-off 
of 4 ng/L for hs-TnT at T2, and not admission, as being 
sufficient for exclusion of ischaemia at PET-CT and effec-
tive decision-making process in a low-risk ACS profile 
population. Indeed, no patient with hs-TnT values at T2 
and T6 below this cut-off had ischaemia at PET-CT and 
none of them experienced MACE. The proportion of 
patients in the present study with hs-TnT <4 ng/L at T2 
was 35% (17 patients) and at T6 was 38% (18 patients). 
Accordingly, using an algorithm to allow the discharge 
of patients with a low-risk of ACS, based on a cut-off 
of 4 ng/L at T2 without any stress imaging, would have 
allowed these patients to have been discharged with a 
marginal probability of an occurrence of any MACEs at 
the 30-day follow-up. In a prospective cohort study of 
patients with suspected ACS, Shah et al concluded that 
low plasma troponin concentrations identify two-thirds 
of patients at very low risk of cardiac events who could 
be discharged from the hospital.19 However, in this 
study, the outcomes were index myocardial infarction, 
subsequent myocardial infarction or cardiac death at 
30 days. In our study, we further support the safety of 
proposed hs-TnT algorithm, by showing no ischaemia 
in PET-CT for patients in the rule-out zone in a prese-
lected low-risk population. However, even if the strategy 
of ruling-out AMI with single value of hs-TnT ranging 
from 3 to 5 ng/L appears safe (as reported in a recent 
meta-analysis20), safety concern remains regarding 
patients who present <3 hours after symptom onset.
Regarding the hs-TnT assay’s performance in the 
detection of myocardial ischaemia, it showed a low posi-
tive predictive value for detecting myocardial ischaemia 
at PET-CT in this specific population with a low-risk 
profile. Indeed, the lowest diagnostic accuracies in our 
study (44%, 48% and 50%) were observed at the 4 ng/L 
cut-off at T0, T2 and T6, respectively. On the other 
hand, the highest diagnostic accuracies were found with 
cut-off values of 19 , 18 and 21 ng/L at T0, T2 and T6, 
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respectively, but with lower negative predictive values 
(93%, 91% and 91%). In other words, hs-TnT seems 
to be an excellent biomarker for excluding the diag-
nosis of myocardial ischaemia at PET-CT, rather than 
for detecting it in this specific population. Considering 
the combined accuracy for ruling-in and ruling-out, 
the algorithm of 2-hour change in hs-Tn level seems 
to outperform a single measure, what was shown and 
validated for hs-TnT in a general cohort of patients 
with chest pain.21 Nevertheless, an algorithm based on 
hs-TnT measurements, coupled with a PET-CT stress 
test, seems to diagnose functionally significant coronary 
artery stenosis correctly at angiogram if hs-TnT ≥4 ng/L. 
This assumption should be verified by using a coronary 
angiogram for all patients.
limitation
One major limitation of the present study is its small 
number of participants, particularly those with a positive 
PET-CT. Another limitation is a verification bias, as coro-
nary angiograms were not performed on patients with 
negative PET-CT. Indeed, the study investigated a low-risk 
ACS population, in which an invasive diagnostic strategy 
is not indicated. However, it could also be argued that 
all these patients had a negative PET-CT and no MACE 
during 30 days of follow-up.
conclusIon
In conclusion, we found that a cut-off <4 ng/L at T2 
provided excellent negative predictive values (100%) 
for the exclusion of myocardial ischaemia as measured 
by PET-CT in a low-risk profile ACS population. Further-
more, in patients with hs-TnT ≥4 ng/L, a strategy based 
on a PET-CT ischaemia detection appears to be appro-
priate. These results should be confirmed in the study of 
a larger sample population.
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